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purification process and pasteurisation, that can affect the 
treatment outcomes. The lactoferrin dose used in previous 
studies varied widely from a fixed dose of 100 mg per day4 
to a maximum dose of 300 mg/kg per day.7 It is not clear 
which is the best lactoferrin dose. Kaufman and colleagues8 
in the USA have done a safety and tolerability study 
in 30 very low birthweight infants randomly assigned 
to daily 100, 200 or 300 mg/kg of bovine lactoferrin. 
The authors found that the intervention was safe,8 and 
detected bovine lactoferrin levels in plasma and urine, and 
high levels in saliva, with all three doses.9 The timing of the 
lactoferrin administration is also important because early 
administration might better protect by promoting cell 
proliferation and maturation of the immature infant gut, 
decreasing intestinal permeability and preventing bacterial 
translocation from the gut to the bloodstream.
The LIFT meta-analysis, despite including their 
own study and the ELFIN study, both without 
significant results, concluded that bovine lactoferrin 
supplementation does reduce the risk of late-onset sepsis. 
Therefore, lactoferrin is still a treatment option to reduce 
late-onset sepsis in preterm infants; however, additional 
research is needed to improve the certainty in the 
evidence, and before it becomes a standard of care in the 
neonatal units. An ideal design would be a multicentre 
trial in infants born weighing less than 1500 g, assessing 
the effect of daily 100, 200, and 300 mg/kg lactoferrin 
doses, and using the same commercial lactoferrin, 
same control groups, and same outcome definition 
(including both culture-confirmed and clinically-defined 
sepsis with the same clinical, laboratory, and treatment 
criteria). Ideally this trial should be done in low-income 
and middle-income countries with the highest burden 
of neonatal infections, where the potential benefit is 
expected to have the largest effect.
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ADHD management during the COVID-19 pandemic: 
guidance from the European ADHD Guidelines Group
The coronavirus disease 2019 (COVID-19) pandemic 
is creating unprecedented challenges at every level of 
society. Individuals with neurodevelopmental disorders, 
such as attention-deficit hyperactivity disorder (ADHD), 
are particularly vulnerable to the distress caused by the 
pandemic and physical distancing measures, and they 
might display increased behavioural problems. The crisis 
also poses several important questions for clinicians 
on how best to deliver care within the new restrictions. 
Therefore, the European ADHD Guidelines Group 
(EAGG) has developed guidance on the assessment 
and management of ADHD during the COVID-19 virus 
pandemic (see full guidance in the appendix).
Given the requirement for physical distancing, all 
relevant service provision should continue via telephone 
or appropriate online video technology, in line with 
current recommendations for the use of telepsychiatry 
(eg, guidance from the UK Royal College of Psychiatrists1 
or the American Psychiatric Association2). The COVID-19 
crisis can be particularly challenging for adolescents, and 
even more so for those with ADHD. Schools and teachers 
should try to monitor all their students but should include 
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those with ADHD, especially adolescents, as a priority 
group, because of their disorganisation and increased 
level of risk. For example, are they participating in online 
classes, and are they submitting their tasks? Are there 
concerns about their social and emotional wellbeing?
For families with children with ADHD, the EAGG 
recommends the use of behavioural parenting strategies 
because they improve parenting and have beneficial 
effects in reducing oppositional defiant and disruptive 
behaviour, which is common in ADHD.3 Under the current 
circumstances, when face-to-face support is not possible, 
parents will have to rely on self-help versions of evidence-
based systems. The efficacy of some of these systems are 
supported by trial evidence.4–6 Some online systems have 
also been shown to have value.7 However, parents must 
be cautious and avoid paying for untested applications 
that could do more harm than good. The EAGG guidelines 
highlights six essential messages (appendix p 14), 
including building the child’s self-confidence and making 
sure all family members know what is expected of them. 
In relation to other non-pharmacological strategies, 
individuals using neurofeedback or cognitive training 
should be encouraged to continue practising transfer 
exercises during homework and new challenges.
Individuals with ADHD should, if clinically indicated 
and as recommended in standard national guidelines, 
be offered the opportunity to start on a pharmacological 
treatment after completion of the initial assessment or, 
if already on medication, continue with this as usual. 
Being prevented access to pharmacological treatment 
after the initial assessment or failure to continue 
ongoing medication could increase health risks related 
to COVID-19, because behaviour related to ADHD could 
become more disorganised and poorly controlled at 
this time, adversely impacting the ability to comply 
with requirements for physical distancing. We hope 
that regulatory authorities will allow for some flexibility 
around restrictions to accessing ADHD medications 
during the COVID-19 outbreak to ensure that patients 
receive their medication in a timely manner.
Parents of children with ADHD and adolescents or adults 
with ADHD should avoid increasing doses or adding doses 
(beyond those prescribed) to manage a crisis or stress 
related to confinement. Similarly, the use of antipsychotic 
medications to manage disruptive behaviour or the use of 
sedatives when not clinically indicated should be avoided. 
In our previous recommendations,8 we stated that “the 
risk-benefit balance of drug holidays during weekends 
must be taken into account and better investigated”. 
Given that family confinement and physical distancing 
might exacerbate ADHD-related risks, we see no strong 
rationale to introduce weekend drug holidays during the 
current crisis.
Routine cardiovascular clinical examination and face-
to-face monitoring for individuals with ADHD without 
any cardiovascular risk factors could be postponed 
until routine face-to-face visits are reinstated, because 
currently the risks of conducting face-to-face assessments 
in this patient group outweigh the benefits of cardiac 
monitoring. If possible, monitoring of blood pressure 
and heart rate using home blood pressure machines is 
recommended, following the guidance detailed in the 
appendix (p 15). Patients should contact their prescribers 
should they experience any emerging cardiovascular 
symptoms (eg, chest pain, prolonged palpitations, 
and breathing difficulties), or any other concerning 
symptoms.
Although sleep-onset delay is a possible adverse event 
during psychostimulant treatment, sleep disruption can 
be caused by other factors that could be associated with 
the COVID-19 outbreak, such as stress, late-morning 
waking, and disruption of daily routines. Appropriate 
sleep hygiene should be implemented or reinforced in 
preference to increasing the doses of melatonin beyond 
the therapeutic range (up to 5–6 mg nocte each night9).
Headache can occur during treatment with psycho-
stimulants. Given the uncertainty around possible 
un favourable effects of ibuprofen in patients with 
COVID-19,10 paracetamol should be preferred over 
ibuprofen for pain management.
In summary, COVID-19 and the related physical 
distancing measures are presenting many challenges 
for children, young people, and their families, and these 
challenges are likely to be considerably greater for those 
with ADHD. It will therefore be important to draw 
upon the strategies routinely recommended in parent-
focused ADHD interventions, as well as mental-wellbeing 
interventions for children and young people. The inability 
to do routine, face-to-face clinical visits to initiate and 
monitor medication should not be viewed as an absolute 
contraindication to pharmacotherapy. Instead, the risks 
and benefits of initiating or maintaining medication 
under the COVID-19 restrictions implemented in some 
countries should be carefully considered. If the use of 
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medication is deemed desirable, strategies for remote 
monitoring should be implemented.
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The immune system of children: the key to understanding 
SARS-CoV-2 susceptibility?
Humanity has repeatedly faced epidemics of known 
and novel pathogens and the immune system has 
adapted to survive. Since severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) is a new zoonotic 
pathogen, there is no pre-existing immunity and the 
whole of humanity is susceptible to infection and 
developing COVID-19 disease.
Adults can be infected with different outcomes, from 
asymptomatic, mild, moderate to severe disease, and 
death. Children can also be infected by SARS-CoV-2, 
but most paediatric cases with laboratory-confirmed 
SARS-CoV-2 infection are mild; severe COVID-19 disease 
in children is rare.1
Children are more vulnerable to other infections; thus, 
the important question arises—why are children less 
susceptible to COVID-19 disease compared with adults? 
So far, there is no evidence of a lower degree of expression 
or function of the SARS-CoV-2 receptor (namely ACE2) in 
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